1-8 of 8
Greg P. Coffey
Close
Sort by
Journal Articles

Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy or in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

Paul A. Hamlin, Manish R. Patel, Don Stevens, Brian T. Hess, Javier Munoz, Tatyana A. Feldman, Sonali M. Smith, Greg P. Coffey, Muhtarjan Osman, Jaymes S Holland, Cristina B Guzman, Stephen D. Smith
Journal: Blood
Blood (2021) 138 (Supplement 1): 2423.
https://doi.org/10.1182/blood-2021-148313
Published: 2021
Journal Articles

Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Steven M. Horwitz, Tatyana A. Feldman, Jing C. Ye, Michael S. Khodadoust, Javier Munoz, Paul A. Hamlin, Youn H. Kim, Ryan A. Wilcox, Manish R. Patel, Greg P. Coffey, Muhtarjan Osman, Jaymes S Holland, Cristina B Guzman, Sonali M. Smith
Journal: Blood
Blood (2021) 138 (Supplement 1): 622.
https://doi.org/10.1182/blood-2021-148352
Published: 2021
Journal Articles

Genetic or CD40L-Mediated Loss of Iκbα Is Associated with Resistance to the Dual SYK/JAK Inhibitor Cerdulatinib in DLBCL Cell Lines

Greg P Coffey, PhD, Jiajia Feng, MD, Sabah Kadri, PhD, Y. Lynn Wang, MD PhD, Pin Lu, PhD, Shruti Sharma, PhD, Jeremy Segal, PhD, Glenn Michelson, MD, Anjali Pandey, PhD, John T. Curnutte, MD PhD, Pamela B. Conley, PhD
Journal: Blood
Blood (2016) 128 (22): 2768.
https://doi.org/10.1182/blood.V128.22.2768.2768
Published: 2016
Journal Articles

Regulation of B-Cell Receptor Signalling By the Tumour Microenvironment in Chronic Lymphocytic Leukemia (CLL) and Its Impact on Adhesion and miRNA Expression

Matthew D Blunt, PhD, Rachel Dobson, BSc(Hons), Lindsay D Smith, PhD, Jonathan C. Strefford, Pamela B. Conley, PhD, Anjali Pandey, PhD, Andrew J Davies, FRCP PhD, Peter M Johnson, MA, MD, Graham Packham, PhD, Freda K Stevenson, DPhil, Francesco Forconi, MD DM, PhD FRCPath, Greg P Coffey, PhD, Andrew J Steele, PhD
Journal: Blood
Blood (2016) 128 (22): 351.
https://doi.org/10.1182/blood.V128.22.351.351
Published: 2016
Journal Articles

Dual SYK/JAK Inhibition Overcomes Ibrutinib Resistance in Chronic Lymphocytic Leukemia

Yue Lynn Wang, MD PhD, Pin Lu, PhD, Greg P Coffey, PhD, Anjali Pandey, PhD, Ailin Guo, PhD MD
Journal: Blood
Blood (2016) 128 (22): 5377.
https://doi.org/10.1182/blood.V128.22.5377.5377
Published: 2016
Journal Articles

Predicting Cerdulatinib Therapeutic Concentrations in Patients with Relapsed/Refractory B Cell Malignancies Using Preclinical Models and Clinical PK/PD and Tumor Response Correlates

Greg P. Coffey, PhD, Jiajia Feng, MD, Glenn Michelson, MD, Janet Leads, PhD, John T. Curnutte, MDPhD, Anjali Pandey, PhD, Pamela B. Conley, PhD
Journal: Blood
Blood (2015) 126 (23): 3706.
https://doi.org/10.1182/blood.V126.23.3706.3706
Published: 2015
Journal Articles

Clinical and Correlative Results of a Phase 1 Study of Cerdulatinib (PRT062070) a Dual SYK/JAK Inhibitor in Patients with Relapsed/Refractory B Cell Malignancies

Paul A Hamlin, Jr., MD, Ian Flinn, MD, Nina wagner-Johnston, MD, Jan A Burger, MD PhD, Glenn Michelson, MD, Anjali Pandey, PhD, Matt Birrell, Greg P. Coffey, PhD, Janet M Leeds, PhD, John T. Curnutte, MDPhD, Manish R. Patel, MD
Journal: Blood
Blood (2015) 126 (23): 3929.
https://doi.org/10.1182/blood.V126.23.3929.3929
Published: 2015
Journal Articles

The Syk\Jak Inhibitor Cerdulatinib (PRT062070) Shows Promising Preclinical Activity in Chronic Lymphocytic Leukemia By Antagonising B Cell Receptor and Microenvironmental Signalling

Matthew D Blunt, PhD, Jack Parnell, BSc(hons), Marta Larrayoz, PhD, Lindsay Smith, PhD, Rachel Dobson, BSc(Hons), Jonathan C Strefford, PhD, Freda K Stevenson, DPhil, Francesco Forconi, MD DM, PhD FRCPath, Andrew J Davies, MRCP, Peter W Johnson, MD, Graham Packham, PhD, Greg P. Coffey, PhD, Mark S Cragg, PhD, Andrew J Steele, PhD
Journal: Blood
Blood (2015) 126 (23): 1716.
https://doi.org/10.1182/blood.V126.23.1716.1716
Published: 2015